Sinocelltech Group Company Description

Sinocelltech Group Limited, a biotech company, engages in the research and development, and industrialization of recombinant proteins, monoclonal antibodies, and vaccines in China.

The company offers AnpingxiA (repertuzumab injection), an anti-tumor product; Anjiayin for the treatment of the rare disease hemophilia A; coronavirus 2-valent, a trimer protein vaccine; and mutant strain recombinant protein vaccines SCTV01C and SCTV01E.

Its pipeline products include SCT630 used for the treatment of autoimmune diseases; SCT510 for the treatment of solid tumors; SCT-I10A, a monoclonal antibody injection which is in phase 3 trials for the treatment of solid tumors; SCTV01, a new generation vaccine which is in phase 3 trials for the treatment of corona virus; SCT510 for the treatment of solid tumors; SCT200, a monoclonal antibody injection for the treatment of solid tumors; and SCT1000, which is in phase 3 clinical trials for the treatment of human papillomavirus, as well as SCTA01 which is in phase 2/3 clinical research trials for the treatment of SARS COV-2.

The company was founded in 2007 and is based in Beijing, China. Sinocelltech Group Limited operates as a subsidiary of Lhasa Alike Investment Consulting Co., Ltd.

Sinocelltech Group Limited

Country	China
Founded	2007
Industry	Biotechnology
Sector	Healthcare
Employees	2,313
CEO	Liangzhi Xie

Contact Details

Address: No. 31 Kechuang 7th Street Beijing, 100176 China
Phone	86 10 5862 8288
Website	sinocelltech.com

Stock Details

Ticker Symbol	688520
Exchange	Shanghai Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	CNE100003ZL3
SIC Code	2836

Key Executives

Name	Position
Dr. Liangzhi Xie Ph.D.	Chairman of the Board and GM
Dr. Yang Wang	Deputy GM and Director
Fanbin Pan	Head of Engineering Equipment Department
Li Ming Tang	Deputy GM, Secretary of the Board and Director